NEW YORK, April 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN), Abbott Laboratories (NYSE: ABT), Express Scripts Holding Company (NASDAQ: ESRX), Zoetis Inc. (NYSE: ZTS), and Edwards Lifesciences Corp. (NYSE: EW). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Amgen Inc. Analyst Notes
On March 30, 2014, Amgen Inc. (Amgen) released new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C). The data showed that the drug showed reduction in LDL cholesterol of 37% - 39%, compared to ezetimibe in patients with high cholesterol who cannot tolerate statins. Compared to those given placebo, the drug resulted in reduction in LDL of 55% - 76%. The results of the two studies of Amgen's evolocumab, presented at the American College of Cardiology meeting in Washington, showed that the drug will help patients who are on a moderate or high-intensity statin and not adequately controlled, as well as patients who cannot tolerate statins and are in need of an alternate treatment option to help lower their LDL cholesterol levels. According to the Centers for Disease Control and Prevention, more than 71 million American adults have high LDL-C, or "bad" cholesterol. The positive study results were welcomed by investors as the stock of Amgen gained 2.31% to close at $123.34 on March 31, 2014. The full analyst notes on Amgen Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04022014/AMGN/report.pdf
--
Abbott Laboratories Analyst Notes
On March 28, 2014, Abbott Laboratories (Abbott) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Supera Peripheral Stent System that treats people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). The approval of Supera Peripheral Stent System is based on data from the SUPERB clinical trial, which showed that the Supera stent proved highly effective in opening up blocked blood vessels in the upper leg, even in difficult cases. Also, it observed that during the first year after treatment with the Supera stent, there were no stent fractures, and at two years there was a very low stent fracture rate of 0.5%. The approval gives Abbott rapid entry into one of the fastest-growing segments of the peripheral stent market. Abbott expanded its product portfolio with the Supera stent, which already has a CE mark in Europe, through the acquisition of IDEV Technologies in August 2013. The full analyst notes on Abbott Laboratories are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ABT/report.pdf
--
Express Scripts Holding Company Analyst Notes
Express Scripts Holding Company (Express Scripts) posted on its Events calendar that the Company will hold its Annual Shareholder Meeting on May 7, 2014 at 8:00 a.m. CT at the Company's principal Executive Offices at One Express Way, Saint Louis, Missouri. Express Scripts is headquartered in St. Louis, and provides integrated pharmacy-benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The full analyst notes on Express Scripts Holding Company are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ESRX/report.pdf
--
Zoetis Inc. Analyst Notes
On March 26, 2014, Zoetis Inc. (Zoetis) announced its Q2 2014 dividend of $0.072 per share payable on June 2, 2014 to holders of record on April 28, 2014. This dividend represents an increase of 11% from the quarterly dividend rate paid by animal health company in 2013. The stock of the Company has slipped 11.42% in Q1 2014 amidst weaker-than-expected full-year 2014 guidance. The Company, which swung to profit in Q4 2013 with net income of $105 million versus net loss of $10 million in Q4 2012, reported a full-year 2014 guidance that was below analysts' estimates polled by Reuters. For full year 2014, Zoetis expects revenues in the range of $4.65 billion to $4.75 billion, and EPS in the range of $1.15 to $1.21 per share. The full analyst notes on Zoetis Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ZTS/report.pdf
--
Edwards Lifesciences Corp. Analyst Notes
On March 30, 2014, Bloomberg reported that Edwards Lifesciences Corp.'s (Edwards) second generation Sapien XT, which is used to repair a calcified aortic valve in the heart, performed better than the closest rival's device in a head-to-head comparison. Intensifying the race to acquire a developing market for heart valves that can be inserted without open-heart surgery, a new group of researchers found that Edwards' Sapien XT had about the same death rate as the competitor's device, and was easier to insert. Bloomberg further reported that the German study of 241 patients concluded that doctors were able to successfully implant Sapien XT in 96% of patients, compared with 78% for the rival's device. The full analyst notes on Edwards Lifesciences Corp. are available to download free of charge at:
http://www.AnalystsReview.com/04022014/EW/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
